Navigation Links
Study Models Impact Of Anthrax Vaccine

Rapidly distributing antibiotics to people exposed to anthrax spores during a bioterrorist attack, could by itself, prevent about 70 percent of anthrax infections from occurring, according to researchers from the Johns Hopkins Bloomberg School of Public Health. To increase the prevention rate to 90 percent, their study found that at least 63 percent of the population would need to be immunized with vaccine before an anthrax attack, which might not be practical. However, the study found that anthrax vaccination given even after an attack could be beneficial in reducing the length of time antibiotic treatment would be needed. These findings could be an important tool for policymakers who must develop effective strategies for containing an anthrax outbreak. The study is published in the December 16, 2004, edition of Nature.

The Hopkins researchers developed a probability model to predict how many cases of anthrax could be prevented under varying conditions. The study found that about 70 percent of anthrax cases could be prevented if antibiotics were distributed within 6 days after exposure and patients were to take them for 60 days. Prevention rates dropped below 50 percent if antibiotics were delayed more than 10 days. In 2001, some postal workers did not begin taking antibiotics until 9 days after exposure. The current licensed anthrax vaccine requires six doses over an 18-month period to provide immunity. The researchers looked at what impact a new and improved anthrax vaccine could have, and evaluated a range of vaccine characteristics, which could begin to provide immunity ranging between 7 and 28 days. When vaccine was distributed along with antibiotics after an attack, the researchers calculated that vaccine prevented few additional cases from occurring when compared to just rapid use of antibiotics. However, they found that if the vaccine is 95 percent effective, it could reduce the time that antibiotics would be needed up to 43 days. An 80 percent effec tive vaccine could reduce time on antibiotics by up to 23 days. The vaccine could also prevent cases if an antibiotic-resistant strain of anthrax were used in an attack. “Our study highlights the need for rapid distribution of antibiotics to minimize casualties from an anthrax outbreak,?explained Ron Brookmeyer, PhD, lead author of the study and professor in the Department of Biostatistics at the Bloomberg School of Public Health. “But a long course of antibiotics is not ideal, and a new improved anthrax vaccine could be especially helpful in reducing duration of antibiotic treatments.?
'"/>

Source:Johns Hopkins Bloomberg School of Public Health


Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Emory Study Tests Bone Marrow Stem Cells to Improve Circulation in Legs
3. UCLA Study Shows One-Third of Drug Ads in Medical Journals Do Not Contain References Supporting Medical Claims
4. Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible
5. Study Links Ebola Outbreaks To Animal Carcasses
6. Breakthrough Microarray-based Technology for the Study of Cancer
7. NYU Study Reveals How Brains Immune System Fights Viral Encephalitis
8. Study finds more than one-third of human genome regulated by RNA
9. Leukemia Drug Breakthrough Study In New England Journal Of Medicine
10. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
11. New Study from Affymetrix Laboratories Points to Changing View of How Genome Works

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/11/2017)... April 11, 2017 NXT-ID, Inc. (NASDAQ: ... company, announces the appointment of independent Directors Mr. Robin ... its Board of Directors, furthering the company,s corporate governance and ... Gino Pereira ... look forward to their guidance and benefiting from their considerable ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
(Date:4/5/2017)... KEY FINDINGS The global market for stem ... 25.76% during the forecast period of 2017-2025. The rise ... growth of the stem cell market. Download ... The global stem cell market is segmented on the ... cell market of the product is segmented into adult ...
Breaking Biology News(10 mins):
(Date:4/27/2017)... RESEARCH TRIANGLE PARK, N.C. , April ... UTHR ) today announced that its Board of ... of the company,s common stock. This program will became ... 2017. Purchases may be made in the open market, ... time to time as determined by United Therapeutics, management ...
(Date:4/27/2017)... ... , ... Mitotech S.A, a Luxembourg based clinical stage biotechnology company, announced positive ... a rare devastating genetic disease that leads to a sudden and rapid loss of ... patients carrying 11778, 14484 and 3460 mutations and having experienced the onset of symptoms ...
(Date:4/27/2017)... ... April 27, 2017 , ... During the ... review how testing for 1,25-Dihydroxyvitamin D can enhance clinical practice. Participants will learn ... 1,25 dihydroxyvitamin D. , Dr. Gregory Plotnikoff, senior consultant with Minnesota Personalized Medicine, ...
(Date:4/27/2017)... USA (PRWEB) , ... April 27, 2017 , ... ... optics and photonics , joined other scientists, researchers, engineers, and industry professionals in ... to strengthen America's ability to compete in the world photonics industry. , This ...
Breaking Biology Technology: